What is Tribute Pharmaceuticals Canada Median PS Value?
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Tribute Pharmaceuticals Canada's Median PS Value or its related term are showing as below:
TBUFF's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.8 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Tribute Pharmaceuticals Canada Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Tribute Pharmaceuticals Canada Median PS Value Chart
Competitive Comparison of Tribute Pharmaceuticals Canada's Median PS Value
For the Drug Manufacturers - Specialty & Generic subindustry, Tribute Pharmaceuticals Canada's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tribute Pharmaceuticals Canada's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tribute Pharmaceuticals Canada's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Tribute Pharmaceuticals Canada's Price-to-Median-PS-Value falls into.
Tribute Pharmaceuticals Canada Median PS Value Calculation
10-Year Median PS Ratio is 0.
Tribute Pharmaceuticals Canada's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.214.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tribute Pharmaceuticals Canada (OTCPK:TBUFF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Tribute Pharmaceuticals Canada's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.93
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tribute Pharmaceuticals Canada Median PS Value Related Terms
Thank you for viewing the detailed overview of Tribute Pharmaceuticals Canada's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBUFF has been successfully added to your 